Adagio Medical Holdings, Inc Common Stock (ADGM)vsEli Lilly and Company (LLY)
ADGM
Adagio Medical Holdings, Inc Common Stock
$0.06
+6.39%
HEALTHCARE · Cap: $2.28M
LLY
Eli Lilly and Company
$1,354.00
-0.79%
HEALTHCARE · Cap: $1.26T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 63110847% more annual revenue ($86.46B vs $137,000). LLY leads profitability with a 31.9% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 74/100 (B).
ADGM
Avoid33
out of 100
Grade: F
LLY
Strong Buy74
out of 100
Grade: B
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 75.6% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 68 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 53.7%
Revenue surging 38.6% year-over-year
Generating 8.2B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 30.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ADGM
The strongest argument for ADGM centers on Revenue Growth, Debt/Equity. Revenue growth of 75.6% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.9% and operating margin at 53.7%. Revenue growth of 38.6% demonstrates continued momentum.
Bear Case : ADGM
The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 46.0x leaves little room for execution misses.
Key Dynamics to Monitor
ADGM profiles as a hypergrowth stock while LLY is a growth play — different risk/reward profiles.
LLY carries more volatility with a beta of 0.45 — expect wider price swings.
ADGM is growing revenue faster at 75.6% — sustainability is the question.
LLY generates stronger free cash flow (8.2B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (74/100 vs 33/100), backed by strong 31.9% margins and 38.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adagio Medical Holdings, Inc Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Adagio Medical Holdings, Inc. is an innovative biotechnology firm dedicated to revolutionizing the treatment of cardiac arrhythmias through advanced medical technologies. Utilizing its proprietary platform, the company is spearheading the development of targeted ablation techniques that address significant unmet needs in the electrophysiology sector. Supported by a robust product pipeline and a seasoned leadership team, Adagio represents an attractive investment opportunity for institutional investors seeking growth in the healthcare space while contributing to improved outcomes in cardiac patient care.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?